The central nervous system (CNS) requires a tightly controlled environment free of toxins and pathogens to provide the proper chemical composition for neural function. This environment is maintained by the 'blood-brain barrier' (BBB), which is composed of blood vessels whose endothelial cells display specialized tight junctions and extremely low rates of transcellular vesicular transport (transcytosis) [1] [2] [3] . In concert with pericytes and astrocytes, this unique brain endothelial physiological barrier seals the CNS and controls substance influx and efflux [4] [5] [6] . Although BBB breakdown has recently been associated with initiation and perpetuation of various neurological disorders, an intact BBB is a major obstacle for drug delivery to the CNS [7] [8] [9] [10] . A limited understanding of the molecular mechanisms that control BBB formation has hindered our ability to manipulate the BBB in disease and therapy. Here we identify mechanisms governing the establishment of a functional BBB. First, using a novel tracer-injection method for embryos, we demonstrate spatiotemporal developmental profiles of BBB functionality and find that the mouse BBB becomes functional at embryonic day 15.5 (E15.5). We then screen for BBB-specific genes expressed during BBB formation, and find that major facilitator super family domain containing 2a (Mfsd2a) is selectively expressed in BBB-containing blood vessels in the CNS. Genetic ablation of Mfsd2a results in a leaky BBB from embryonic stages through to adulthood, but the normal patterning of vascular networks is maintained. Electron microscopy examination reveals a dramatic increase in CNS-endothelial-cell vesicular transcytosis in Mfsd2a 2/2 mice, without obvious tight-junction defects. Finally we show that Mfsd2a endothelial expression is regulated by pericytes to facilitate BBB integrity. These findings identify Mfsd2a as a key regulator of BBB function that may act by suppressing transcytosis in CNS endothelial cells. Furthermore, our findings may aid in efforts to develop therapeutic approaches for CNS drug delivery.
1
The central nervous system (CNS) requires a tightly controlled environment free of toxins and pathogens to provide the proper chemical composition for neural function. This environment is maintained by the 'blood-brain barrier' (BBB), which is composed of blood vessels whose endothelial cells display specialized tight junctions and extremely low rates of transcellular vesicular transport (transcytosis) [1] [2] [3] . In concert with pericytes and astrocytes, this unique brain endothelial physiological barrier seals the CNS and controls substance influx and efflux [4] [5] [6] . Although BBB breakdown has recently been associated with initiation and perpetuation of various neurological disorders, an intact BBB is a major obstacle for drug delivery to the CNS [7] [8] [9] [10] . A limited understanding of the molecular mechanisms that control BBB formation has hindered our ability to manipulate the BBB in disease and therapy. Here we identify mechanisms governing the establishment of a functional BBB. First, using a novel tracer-injection method for embryos, we demonstrate spatiotemporal developmental profiles of BBB functionality and find that the mouse BBB becomes functional at embryonic day 15.5 (E15.5). We then screen for BBB-specific genes expressed during BBB formation, and find that major facilitator super family domain containing 2a (Mfsd2a) is selectively expressed in BBB-containing blood vessels in the CNS. Genetic ablation of Mfsd2a results in a leaky BBB from embryonic stages through to adulthood, but the normal patterning of vascular networks is maintained. Electron microscopy examination reveals a dramatic increase in CNS-endothelial-cell vesicular transcytosis in Mfsd2a 2/2 mice, without obvious tight-junction defects. Finally we show that Mfsd2a endothelial expression is regulated by pericytes to facilitate BBB integrity. These findings identify Mfsd2a as a key regulator of BBB function that may act by suppressing transcytosis in CNS endothelial cells. Furthermore, our findings may aid in efforts to develop therapeutic approaches for CNS drug delivery.
Two unique features of the CNS endothelium determine BBB integrity (Extended Data Fig. 1) 
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. One is specialized tight junctions between a single endothelial cell layer lining the CNS capillaries, which form the physical seal between the blood and brain parenchyma 2 . In addition, CNS endothelial cells have lower rates of transcytosis than endothelial cells in other organs 3 . Peripheral endothelial cells display active vesicle trafficking to deliver nutrients to peripheral tissues, whereas CNS endothelial cells express transporters to selectively traffic nutrients across the BBB 1, 3, 11 . However, it is not clear when and how these properties are acquired. Furthermore, the molecular mechanisms that give rise to the unique properties of the CNS endothelium have not been identified. Although recent studies revealed molecular pathways involved in the development of the embryonic BBB [12] [13] [14] [15] [16] [17] [18] [19] , disruption of some of these genes affect vascular network development, making it difficult to determine whether barrier defects are primary or secondary to a broader vascular effect.
We aimed to first identify the developmental time-point when the BBB gains functional integrity, and then use that time window to profile BBBspecific genes when the BBB is actively forming, to maximize the chance of identifying key regulators. The prevailing view has been that the embryonic and perinatal BBB are not yet functional 1 . However, previous embryonic BBB functionality studies were primarily performed by transcardiac tracer perfusion, which may dramatically affect blood pressure, cause bursting of CNS capillaries, and artificially produce leakiness phenotypes 1, 20 . To circumvent these obstacles, we developed a method to assess BBB integrity during mouse development, in which a small volume of tracer is injected into embryonic liver to minimize changes in blood pressure (Fig. 1a , see Supplementary Information for the method).
Using this method, we identified the timing of BBB formation in the developing mouse brain and observed a spatial and temporal pattern of 'functional-barrier genesis' (Fig. 1b) . We found that in E13.5 cortex a 10-kDa dextran tracer leaked out of capillaries and was taken up by nonvascular brain parenchyma cells (Fig. 1b, top panel) . At E14.5, the tracer was primarily restricted to capillaries, but tracer was still detected outside vessels (Fig. 1b, middle panel) . In contrast, at E15.5, the tracer was confined to vessels with no detectable signal in the surrounding brain parenchyma, similar to the mature BBB (Fig. 1b, bottom panel) . The development of BBB functionality differed across brain regions (Supplementary Information and Extended Data Fig. 2 ). These data demonstrate that following vessel ingression into the neural tube, the BBB gradually becomes functional as early as E15.5.
Based on the temporal profile of BBB formation, we compared expression profiles of BBB (cortex) and non-BBB (lung) endothelium at E13.5, using an Affymetrix array (Supplementary Information), and identified transcripts with significantly higher representation in cortical than lung endothelium (Fig. 2) . These transcripts included transporters, transcription factors, and secreted and transmembrane proteins (Fig. 2c ). We were particularly interested in transmembrane proteins, owing to their potential involvement in cell-cell interactions that regulate BBB formation.
One of the genes identified, Mfsd2a, had 78.8 times higher expression in cortical endothelium than in lung endothelium (Fig. 3a) . In situ hybridization showed prominent Mfsd2a mRNA expression in CNS vasculature but no detectable signal in vasculature outside the CNS, such as in lung or liver (Fig. 3b) . Moreover, both Mfsd2a mRNA and Mfsd2a protein were absent in the choroid plexus vasculature, which is part of the CNS but does not possess a BBB 1 (Fig. 3c, d, g ). Mfsd2a expression in CNS vasculature was observed at embryonic stages (E15.5), postnatal days 2 and 5 (P2 and P5) and in adults (P90) (Fig. 3b-e and Extended Data Fig. 3 ). Finally, Mfsd2a protein, which is absent in the Mfsd2a 2/2 mice (Fig. 3e ) 21 , was specifically expressed in claudin-5-positive CNS endothelial cells but not in neighbouring parenchyma cells (neurons or glia) or adjacent Pdgfrb-positive pericytes (Fig. 3f) . Previously, Mfsd2a was reported to be a transmembrane protein expressed in the placenta and testis, which have highly restrictive barrier properties 22 . Together with our demonstration of Mfsd2a-specific expression in BBB-containing endothelial cells, this suggests that Mfsd2a may have a role in BBB formation and/or function.
To test this hypothesis, we examined BBB integrity in Mfsd2a 2/2 mice. Using our embryonic injection method, 10-kDa dextran was injected into Mfsd2a 2/2 and wild-type littermates at E15.5. As expected, dextran was confined within vessels of control embryos. In contrast, dextran leaked outside the vessels in Mfsd2a 2/2 embryonic brains and was found in the cortical parenchyma (Fig. 4a) and individual parenchyma cells (quantified as tracer-positive parenchyma cells per unit area of the developing lateral cortical plate; Fig. 4b ). Furthermore, using imaging and spectrophotometric quantification methods 5 , we found that the leaky phenotype persisted in early postnatal (Extended Data Fig. 4 ) and adult ( Fig. 4c) 
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2/2 mice. Because the sequence of Mfsd2a has similarities to the major facilitator superfamily of transporters, and Mfsd2a facilitates the transport of tunicamycin in cancer cell lines 23 , we injected two non-carbohydrate-based tracers of different sizes to rule out the possibility that dextran leakiness is due to interactions with Mfsd2a. Sulfo-NHS-biotin (,550 Da) and horseradish peroxidase (HRP; ,44 kDa) tracers exhibited the leaky phenotype in Mfsd2a 2/2 mice (Extended Data  Fig. 4a, b) . Moreover, a larger molecular weight tracer, 70-kDa dextran, also displayed leakiness in Mfsd2a 2/2 mice (Extended Data Fig. 4d ). In contrast to severe barrier leakage defects (Fig. 4a-c and Extended Data Fig. 4 ), brain vascular patterning was similar between Mfsd2a 2/2 mice and littermate controls. No abnormalities were identified in capillary density, capillary diameter or vascular branching ( Fig. 4d and Extended Data Fig. 5a ), in embryonic (E15.5), postnatal (P4), and adult (P70) brains of Mfsd2a 2/2 mice. Moreover, we found no abnormalities in cortical arterial distribution in adult Mfsd2a 2/2 mice (Extended Data Fig. 5b ). Therefore, Mfsd2a is specifically required for proper formation of a functional BBB but not for CNS vascular morphogenesis in vivo. This result, together with the temporal difference between cortical vascular ingression (E10-E11) and cortical barrier-genesis (E13.5-E15.5), demonstrates that vascular morphogenesis and barrier genesis are distinct processes. We next addressed whether Mfsd2a regulates endothelial tight-junction formation, transcytosis, or both. We examined these properties by electron microscopy in embryonic brains and P90 mice following intravenous HRP injection 2 . Electron microscopy failed to reveal any apparent abnormalities in the ultrastructure of endothelial tight junctions (Fig. 5a ). At E17.5, tight junctions in control and Mfsd2a 2/2 littermates appeared normal, with electron-dense linear structures showing 'kissing points' where adjacent membranes are tightly apposed (Fig. 5a ). In electron micrographs of cerebral cortex in HRP-injected adults, peroxidase activity was revealed by an electron-dense reaction product that filled the vessel lumen. In both control and Mfsd2a 2/2 mice, HRP penetrated the intercellular spaces between neighbouring endothelial cells only for short distances. HRP was stopped at the tight junction, creating a boundary between HRP-positive and HRP-negative regions without leakage through tight junctions (Fig. 5a ). In contrast, CNS endothelium of Mfsd2a 2/2 mice displayed a dramatic increase in the number of vesicles, including luminal and abluminal plasma membrane-connected vesicles and free cytoplasmic vesicles, which may indicate an increased rate of transcytosis (Fig. 5b) . Specifically, pinocytotic events were evidenced by type II lumen-connected vesicles pinching from the luminal plasma membrane. Greater than twofold increases in vesicle number in Mfsd2a 2/2 mice compared to control littermates were observed in different locations along the transcytotic pathway ( Fig. 5 and Extended Data Table 2 ). Furthermore, the HRP reaction product in adult mice was observed in vesicles invaginated from the luminal membrane and exocytosed at the abluminal plasma membrane only in Mfsd2a 2/2 mice ( Fig. 5d ), suggesting that HRP was subject to transcytosis in these animals but not in wildtype littermates (Extended Data Table 2 ). Together, these findings suggest that the BBB leakiness observed in Mfsd2a 2/2 mice was not caused by opening of tight junctions, but rather by increased transcellular trafficking across the endothelial cytoplasm.
Studies using pericyte-deficient genetic mouse models have shown that pericytes can also regulate BBB integrity. These mice had increased vesicle trafficking without obvious junction defects 4, 5 , similar to our observations in Mfsd2a 2/2 mice. We therefore examined the possibilities that Mfsd2a may regulate CNS endothelial transcytosis by modulating pericyte function or that the effect of pericytes on endothelial transcytosis is mediated by Mfsd2a. First, pericyte coverage, attachment to the capillary wall, and pericyte ultrastructure and positioning relative to endothelial cells were normal in Mfsd2a 2/2 mice (Extended Data Fig. 6 ). These data, together with the lack of Mfsd2a expression in pericytes, suggest that the increased transcytosis observed in Mfsd2a 2/2 endothelial cells is not secondary to pericyte abnormalities. Second, a genetic reduction in pericyte coverage can influence endothelial gene expression . Therefore we analysed published microarray data of two pericyte-deficient mouse models 5 and found a dramatic downregulation of Mfsd2a in these mice, with a direct correlation between the reduction of Mfsd2a gene expression and the degree of pericyte coverage (Extended Data Fig. 7a) . Furthermore, immunostaining for Mfsd2a in Pdgfb ret/ret mice 5 revealed a significant decrease in Mfsd2a protein levels in endothelial cells that are not covered by pericytes (Extended Data Fig. 7b-d) . Therefore, it is plausible that the increased vesicular trafficking phenotype observed in pericyte-deficient mice is, at least in part, mediated by Mfsd2a, and that endothelial-pericyte interactions control the expression of Mfsd2a, which in turn controls BBB integrity.
LETTER RESEARCH
We demonstrate that Mfsd2a is required to suppress endothelial transcytosis in the CNS. Because of Mfsd2a's involvement in human trophoblast cell fusion 24 and of our genetic evidence for its role in suppressing transcytosis, we propose that Mfsd2a serves as a cell-surface molecule to regulate membrane fusion or trafficking. Indeed, from immuno-electron-microscopy examination, Mfsd2a protein was found in the luminal plasma membrane and associated with vesicular structures in cerebral endothelial cells, but not in tight junctions (Extended Data Fig. 8 ). At present, it is not clear whether the reported transporter function of Mfsd2a is related to its role in BBB formation.
BBB breakdown has been reported in the aetiology of various neurological disorders [7] [8] [9] [10] , and two separate Mfsd2a-deficient mouse lines were reported to exhibit neurological abnormalities, such as ataxic behaviour 21, 25 . Finding a novel physiological role of Mfsd2a may provide a valuable tool to address how a non-functional BBB could affect brain development. In addition, our finding also highlights the importance of the transcytotic mechanism in BBB function, whereas most previous attention has been focused on potential BBB leaks through intercellular junctions. Indeed, increased numbers of pinocytotic vesicles were observed following acute exposure to external stress inducers in animal models 26 , and have also been observed in human pathological conditions 9 . It will ** *** *** *** *** ** *** *** Supplementary Fig. 7b ). Luminal invaginations (dye uptake, arrows) and release to the basement membrane (abluminal side, asterisk). Scale bars, 100 nm (a, b), 200 nm (c). All data are mean 6 s.e.m. **P , 0.01, ***P , 0.001 (student's t-test).
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be interesting to examine whether Mfsd2a is involved in these pathological and acute assault situations. We cannot be certain that the elevated levels of transcytosis in Mfsd2a 2/2 mice were not due to some form of acute cellular stress, but it is very unlikely. This is because under stress, either cells respond to restore homeostasis or cell death occurs 27 . However, increased transcytosis in Mfsd2a 2/2 mice persists from embryonic stages to adulthood, and up to 6 months of age these mice exhibit no sign of vascular degeneration (Extended Data Fig. 5c ). Our identification of a key molecular player in BBB formation may also aid efforts to develop therapeutic approaches for efficient drug delivery to the CNS. As an accessible cell surface molecule, Mfsd2a is poised to be a potential therapeutic target for BBB restoration and manipulation.
METHODS SUMMARY
The lowest volume of 10-kDa dextran tetramethylrhodamine, lysine fixable (D3312 Invitrogen) that still facilitated full perfusion was injected into the embryonic liver, while keeping the embryo connected to the maternal blood circulation through the umbilical cord. After 3 minutes of tracer circulation, embryonic heads were fixed by immersion in 4% paraformaldehyde (PFA) overnight at 4 uC, cryopreserved in 30% sucrose and frozen in TissueTek OCT (Sakura). Sections of 12 mm were then collected and post-fixed in 4% PFA at room temperature (20-25 uC) for 15 min, washed in PBS and co-stained with either a-PECAM antibody or with isolectin B4 to visualize blood vessels (see Methods for details). P90 HRP injection and E17.5 cortex capillaries transmission electron microscopy (TEM) imaging was done as described previously 
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Animals. Wild-type Swiss-Webster mice (Taconic Farms) were used for embryonic BBB functionality assays and expression profiles. Homozygous Tie2-GFP transgenic mice (Jackson laboratory, strain 003658) were used for BBB transcriptional profiling. Mfsd2a-null mice 21 (Mouse Biology Program, University of California, Davis -MMRRC strain 032467-UCD, B6;129S5-Mfsd2atm1Lex/Mmucd) were maintained on C57Bl/6;129SVE mixed background and used for testing the involvement of Mfsd2a in barrier genesis. Mfsd2a-null mutant mice were genotyped using the following PCR primers: 59-CCTGGTTTGCTAAGTGCTAGC-39 and 59-GTTCACTGGCTTGGAGGATGC-39, which provide a 210-bp product for the Mfsd2a wild-type allele; and 59-CACTTCCTAAAGCCTTACTTC-39 and 59-GC AGCGCATCGCCTTCTATC-39, which provide a 301-bp product for the Mfsd2a-knockout allele.
Pregnant mice were obtained following overnight mating (day of vaginal plug was defined as embryonic day 0.5).
All animals were treated according to institutional and US National Institutes of Health (NIH) guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at Harvard Medical School. Immunohistochemistry. Tissues were fixed with 4% paraformaldehyde (PFA) at 4 uC overnight, cryopreserved in 30% sucrose and frozen in TissueTek OCT (Sakura). Tissue sections were blocked with 5% goat serum, permeabilized with 0.5% Triton X-100, and stained with the following primary antibodies: a-PECAM (1:500; 553370, BD PharmingenTM), a-Claudin5 (1:400; 35-2500, Invitrogen), a-Mfsd2a (1:500; Cell Signaling Technologies (under development)), a-Pdgfrb (1:100; 141402, eBioscience), a-CD31 (1:100; 558744, BD PharmingenTM), a-SMA (1:100; C6198, Sigma Aldrich), followed by 568/488 Alexa Fluor-conjugated secondary antibodies (1:300-1:1000, Invitrogen) or with Isolectin B4 (1:500; I21411, Molecular Probes). Slides were mounted in Fluoromount G (EMS) and visualized by epifluorescence, light, or confocal microscopy. In situ hybridization. Tissue samples were frozen in liquid nitrogen and embedded in TissueTek OCT (Sakura). Sections (18 mm) were hybridized with a digoxigenin (DIG)-labelled mouse Mfsd2a antisense riboprobe (1,524-2,024 bp NM_ 029662) at 60 uC overnight. A sense probe was used to ensure signal specificity. For detection, signals were developed using anti-DIG antibody conjugated with alkaline phosphatase (Roche). After antibody treatment, sections were incubated with BM Purple AP Substrate (Roche). Embryonic BBB permeability assay. The method is based on the well-established adult BBB dye-injection assay with special considerations for the injection site and volume to cater the nature of embryonic vasculature 20, [28] [29] [30] . Four major modifications were made: first, embryos were injected while still attached via the umbilical cord to the mother's blood circulation, minimizing abrupt changes in blood flow. Deeply anaesthetized pregnant mice were used.
Second, taking advantage of the sinusoidal, fenestrated and most permeable liver vasculature, dye was injected using a Hamilton syringe into the embryonic liver and was taken into the circulation in a matter of seconds.
Third, dye volume was adjusted to a minimum that still allows detection in all CNS capillaries after 3 min of circulation. High-fluoresce-intensity dye enables the use of small volumes and facilitates detection at the single-capillary level (10-kDa dextran-tetramethylrhodamine, lysine fixable, 4 mg ml 21 (D3312 Invitrogen), 1 ml for E13.5, 2 ml for E14.5, 5 ml for E15.5).
Fourth, traditional perfusion fixation was omitted, again to prevent damage to capillaries. Instead, fixable dyes were used to allow reliable immobilization of the dye at the end of the circulation time (relatively small embryonic brain facilitates immersion fixation).
Embryonic heads were fixed by immersion in 4% PFA overnight at 4 uC, cryopreserved in 30% sucrose and frozen in TissueTek OCT (Sakura). Sections of 12 mm were then collected and post-fixed in 4% PFA at room temperature for 15 min, washed in PBS and co-stained with either a-PECAM antibody or with isolectin B4 to visualize blood vessels. All embryos from each litter were injected blind before genotyping. Postnatal and adult BBB permeability assay. P2-P5 pups were deeply anaesthetized and three methods were used: the first method involved injection of 10 ml of 10-kDa or 70-kDa dextran tetramethylrhodamine (4 mg ml 21 D3312 Invitrogen) into the left ventricle with a Hamilton syringe. After 5 min of circulation, brains were dissected and fixed by immersion in 4% PFA at 4 uC overnight, cryopreserved in 30% sucrose and frozen in TissueTek OCT (Sakura). Sections of 12 mm were collected and post-fixed in 4% PFA at room temperature for 15 min, washed in PBS and co-stained to visualize blood vessels with either a-PECAM primary antibody (1:500; 553370, BD Pharmingen), followed by 488-Alexa Fluor conjugated secondary antibody (1:1000, Invitrogen) or with isolectin B4 (1:500; I21411, Molecular Probes).
The second method involved injection of 10 ml of HRP type II (5 mg ml
21
P8250-50KU Sigma-Aldrich) into the left heart ventricle with a Hamilton syringe.
After 5 min of circulation brains were dissected and immersion fixed in 2% glutaraldehyde in 4% PFA in cacodylate buffer (0.1 M, pH 7.3) at room temperature for 1 h then at 4 uC for 3 h then washed in cacodylate buffer overnight. Corticalvibratome sections (100 mm) were processed in a standard DAB reaction. The third method involved the use of EZ-link NHS-sulfo-biotin as a tracer, as described previously 17 .
Imaging. Nikon Eclipse 80i microscope equipped with a Nikon DS-2 digital camera was used to image HRP tracer experiments, vasculature density and pericyte coverage comparisons and expression analyses. Zeiss LSM 510 META upright confocal microscope was used to image Dextran and NHS-sulfo-biotin BBB permeability assays. A Nikon FluoView FV1000 laser scanning confocal microscope and a Leica SP8 laser scanning confocal microscope were used for imaging Mfsd2a and pericyte marker immunohistochemistry. Images were processed using Adobe Photoshop and ImageJ (NIH). Morphometric analysis of vasculature. Coronal sections (25-mm thick) of E15.5, P4 and P70 brains were immunostained for PECAM. For vascular density and branching, confocal images were acquired with a Nikon FluoView FV1000 laser scanning confocal microscope and maximal projection images (5 per animal) were used for quantifications. The number of branching points was manually counted. Capillary density was quantified using MetaMorph software (Universal Imaging, Downingtown, Pennsylvania) by measuring the area occupied by PECAM-positive vessels per cortical area. The mean capillary diameter was measured manually in ImageJ from cross-sectional vascular profiles (20 per animal) on micrographs (5-7 per animal) taken under a 360 objective with a 32 digital zoom.
For artery distribution quantification, 25-mm-thick sections (P60) were stained for smooth muscle actin (SMA) and PECAM. The proportion of PECAM-positive brain vessels with artery (SMA) identity was quantified using MetaMorph and expressed as percent of controls. Quantification was carried out blind. Quantification of cortical-vessel pericyte coverage. Pericyte coverage of cortex vessels in Mfsd2a 2/2 and wild-type littermate control mice was quantified by analysing the proportion of total claudin-5-positive endothelial length also positive for the pericyte markers CD13 or Pdgfrb. Immunostaining was performed on 20-mm sections of P5 cortex. In each animal, 20 images of 10 different sections were analysed. Microvasculature was found to be completely covered by pericytes in both control and Mfsd2a 2/2 mice and therefore no error bars are presented for the average pericyte coverage in Extended Data Fig. 6a, b (n 5 3) . All the analysis was done with ImageJ (NIH). Quantification was carried out blind. Quantification of vessel leakage. Epifluorescence images of sections from injected tracer and co-stained with lectin were analysed manually with ImageJ (NIH). Coronal cortical sections (12 mm) of the same rostrocaudal position were used for the analysis. The same acquisition parameters were applied to all images and the same threshold was used. Tracer-positive cells found outside a vessel (parenchyma) were used as a parameter for leakage. For each embryo, at least 20 sections of a fixed lateral cortical plate area were scored. Four arbitrary leakage groups were classified based on the number of tracer parenchyma positive cells per section (0, 1-5, 5-10 and 10-40). Average representation of each leakage group was calculated for Mfsd2a 2/2 and control embryos. Quantification was carried out blind.
Spectrophotometric quantification of 10-kDa fluoro-ruby-dextran tracer was carried out from cortical extracts, 16 h after tail-vein injections in adult mice, as described previously 5 . Transmission electron microscopy. TEM imaging of P90 HRP injection and E17.5 cortex capillaries was carried out as described previously 2 . HRP (10 mg (per 20 g); Sigma Aldrich, HRP type II) were dissolved in 0.4 ml of PBS and injected into the tail veins of deeply anaesthetized P90 mice. After 30 min of HRP circulation, brains were dissected and fixed by immersion in a 0.1 M sodium-cacodylate-buffered mixture (5% glutaraldehyde and 4% PFA) for 1 h at room temperature followed by 5 h in PFA at 4 uC. Following fixation, the tissue was washed overnight in 0.1 M sodium-cacodylate buffer and then cut in 50-mm-thick free-floating sections using a vibrotome. Sections were incubated for 45 min at room temperature in 0.05 M Tris-HCl pH 7.6 buffer, containing 5.0 mg per 10 ml of 3-39 diaminobenzidine (DAB, Sigma Aldrich) with 0.01% hydrogen peroxide. Sections were then postfixed in 1% osmium tetroxide and 1.5% potassium ferrocyanide and dehydrated and embedded in epoxy resin. E17.5 samples were processed as the P90 samples without HRP injection and with longer fixation times (2-3 days in room temperature). Ultrathin sections (80 nm) were then cut from the block surface, collected on copper grids, stained with Reynold's lead citrate and examined under a 1200EX electron microscope (JEOL) equipped with a 2k CCD digital camera (AMT). Immunogold labelling for electron microscopy. Mice were deeply anaesthetized and perfused through the heart with 30 ml of PBS followed by 150 ml of a fixative solution (0.5% glutaraldehyde in 4% PFA prepared in 0.1 mM phosphate buffer, pH 7.4), and then by 100 ml of 4% PFA in phosphate buffer. The brain was removed and post fixed in 4% PFA (30 min, 4 uC) and washed in PBS. Coronal brain sections (50-mm thick) were cut on the same day with a vibratome and processed free floating.
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Sections were immersed in 0.1% sodium borohydride in PBS (20 min, room temperature), rinsed in PBS and pre-incubated (2 h) in a blocking solution of PBS containing 10% normal goat serum, 0.5% gelatine and 0.01% Triton. Incubation (24 h, 20-25 uC) with rabbit anti-Mfsd2a (1:100; Cell Signaling Technologies (under development)) primary antibody was followed by rinses in PBS and incubation (overnight, 20-25 uC) in a dilution of gold-labelled goat anti-rabbit IgGs (1:50; 2004, Nanoprobes). After washes in PBS and sodium acetate, the size of immunogold particles was silver-enhanced and sections rinsed in phosphate buffer before processing for electron microscopy. Statistical analysis. Comparison between wild-type and Mfsd2a 2/2 pericyte coverage and spectrophotometric quantification of 10-kDa fluoro-ruby-dextran tracer leakage was performed by a Mann-Whitney U-test (appropriate for small sample size; each embryo was considered as a sample). An unpaired student's t-test was used (GraphPad Prism 4 Software) for comparison between wild-type and Mfsd2a
2/2
for vascular density, artery distribution, number of vesicular types, mean capillary diameter and Mfsd2a expression in pericyte deficient mice. P , 0.05 was considered significant (StatXact Cytel Software Corporation,Cambridge, Massachusetts, USA). Transcriptional profiling. E13.5 Tie2-GFP embryos were micro-dissected for cortex and lungs. Cortex tissue was carefully cleared of the meninges and choroid plexus. FACS purification of GFP-positive cells and GeneChip analysis was performed as described previously 31 . RNA was purified with Arcturus PicoPure RNA isolation kit (Applied biosystems), followed by NuGEN Ovation V2 standard linear amplification and hybridization to Affymetrix Mouse Genome 430 2.0 Array. All material from a single litter (10-13 embryos) was pooled and considered as a biological replicate. Four biological replicates were used. Each biological replicate represents purification from different litters performed on different days. Transcriptional profile analysis of pericyte deficient mice. Expression data from a published study of pericyte-deficient mice 5 were obtained from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo, accession number GSE15892). All microarrays were analysed using the MAS5 probe set condensation algorithm with Expression Console software (Affymetrix). P values were determined using a twotailed student's t-test (n 5 4). Mfsd2a protein expression in Pdgfb ret/ret mice. Brain samples from P10-P14 mice and controls were kindly provided by C. Betsholtz. Sample processing and immunohistochemistry was carried out as described for all other samples in our study. Mfsd2a staining quantification was carried out with 12-mm cortical sagittal sections. Confocal images were acquired with a Nikon FluoView FV1000 laser scanning confocal microscope. Quantification of mean grey value per vascular profile was done with ImageJ (NIH) by outlining vascular profiles according to lectin staining and measuring Mfsd2a intensity in these areas. In all images, Pdgfrb antibody staining was used to test presence of pericytes in quantified vessels. n 5 2 animals per genotype, 60 images quantified of at least 600 vascular profiles per animal. Quantification was carried out blind. High magnification images of capillary cross sections co-staining for endothelium (Glut1, red) and pericytes (Pdgfrb, green) revealed no difference in pericyte-endothelial relationships between wild-type (top panels) and Mfsd2a 2/2 (bottom panels) mice (endothelial nucleus and pericyte nucleus are indicated by single and double asterisks, respectively). d, Electron micrographs of longitudinal capillary sections revealed that pericytes had normal appearance and were well positioned on the vessel walls in Mfsd2a 2/2 adult mice; pericytes were adjacent to endothelial cells and shared a common basement membrane. L, lumen; P, pericyte.
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